Cargando…
Cardiovascular diseases : genetic susceptibility, environmental factors and their interaction /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London, United Kingdom :
Academic Press,
2016.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Cardiovascular Diseases; Cardiovascular Diseases: Genetic Susceptibility, Environmental Factors and their Interaction; Copyright; Dedication; Contents; List of Contributors; Acknowledgments; 1
- Summary ; 2
- Atherosclerosis and Coronary Artery Disease: From Basics to Genetics ; INTRODUCTION; NORMAL ARTERY STRUCTURES; PATHOGENESIS OF ATHEROSCLEROSIS; INITIATION OF ATHEROMA; The Role of Endothelium; The Role of LDL Particles; The Role of Inflammation; Monocyte-Derived Macrophages; LDL and Inflammation; Atheroprotective Mechanisms and Inflammation; Retention of Macrophages.
- T LymphocytesTHE FORMATION OF ATHEROSCLEROTIC PLAQUE; Apoptosis and Efferocytosis of Macrophages; The Role of Vascular Smooth Muscle Cells; Neovascularization; CLINICAL IMPLICATIONS OF ATHEROSCLEROSIS; GENETICS OF CORONARY ARTERY DISEASE; ABO Blood Groups; Lipid-Associated Genes; Other Atherosclerosis-Related Genes; The Role of microRNAs; ATHEROSCLEROSIS: THERAPEUTIC OPTIONS; REFERENCES; 3
- The Role of Genetics in Acute Coronary Syndrome ; INTRODUCTION; CLOPIDOGREL; Metabolism and Pharmacokinetics; Absorption and Role of P-glycoprotein; Hepatic Carboxylation and Oxidation.
- Effect of Genotypic PolymorphismsABCB1; CYP2C19; Nomenclature; CYP2C19*2 and Other Loss-of-Function Alleles; Pharmacokinetics/Pharmacodynamics; Clinical Trials and Meta-analyses; CYP2C19*17 Gain of Function Allele; Incidence of CYP2C19 Alleles in Specific Ethnic Groups; CYP3A4; CYP1A2; Paraoxonase 1; CYP4F2; Platelet Surface Receptors; P2Y12 Receptor; Platelet Endothelial Aggregation Receptor-1; Protease Activated Receptors; Nongenetic Factors; Clopidogrel and Proton Pump Inhibitors; PRASUGREL; Metabolism; Pharmacokinetics, Pharmacodynamics, and Clinical Trials; TICAGRELOR; Metabolism.
- Pharmacokinetics, Pharmacodynamics, and Clinical TrialsCompliance; Drug-Drug Interactions; GENOTYPING ASSAYS; COST-EFFECTIVENESS OF GENOTYPING; GENETIC POLYMORPHISMS RELATED TO ASPIRIN; FUTURE DIRECTIONS; Cilostazol and Role of Genetics; Statins and the Role of Genetics; SUMMARY: ROLE OF GENOTYPING IN ACUTE CORONARY SYNDROME; REFERENCES; 4
- Global Epidemiology and Incidence of Cardiovascular Disease ; INTRODUCTION; GLOBAL BURDEN OF DISEASE: REPORTING METRICS; MEASURING THE GLOBAL BURDEN OF CARDIOVASCULAR DISEASE; Limitations of the Quality and Completeness of Data.
- CHANGES IN TOTAL DISEASE BURDEN VERSUS CVDGLOBAL CARDIOVASCULAR MORTALITY; Global CVD Mortality Rates by WHO Region; Global CVD Mortality Rates by WHO/World Bank Region; Age and Gender Global CVD Mortality Rates; GLOBAL CARDIOVASCULAR DALY; Global CVD Lost DALYs Within WHO Regions; Global CVD Lost DALYs by WHO/World Bank Region; Age and Gender Global CVD Loss of DALYs; RISK FACTORS FOR CVD GLOBALLY; Hypertension; Diabetes Mellitus; Tobacco; Dyslipidemia; Physical Activity; Alcohol Consumption; EPIDEMIOLOGICAL TRANSITION; AGING POPULATION; ETHNICITY; European; Chinese; South Asian; Hispanic.